A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
In this interview, Eric Daar, M.D. discusses how the new coformulation elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) measures up to its predecessor, specifically among older adults.
In general, tenofovir alafenamide (TAF) is safe, with improvements in bone and kidney health over tenofovir disoproxil fumarate (TDF). However, those with severe kidney disease may not see improvements in kidney health, according to a recent study....
A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.